Genmab — Februar 2024
-
Masser af R, begrænset D og tungetunge administrationsomkostninger
-
var det ikke Novod, der kaldte set-uppet for "døde penge"
-
the 50/50 split Genmab wants is a significant hurdle for partnerships with big pharma i believe. and very possibly one of the reasons some of the larger bi-specific deals we have seen over the last few months were not with genmab technology. But i can't blame them for pursuing 50/50, after what happened with JNJ, i would also not want to be in a position like that again...
-
But it's really not that hard - once you have run the safety/dose escalation part of the clinical development, you are in a very different place negotiation-wise. GEN has done very little of this. In fact, it seems they need to partner with other companies to have the necessary tech to even get programs into the clinic
-
Apart from hexa - when was the last time we saw results from the clinic on new programs?
-
how is KYSO the same as the need to enter 50/50 partnerships to get something off the ground?
-
EL, indeed. But where are all the other programs showing clinical promise?
-
So far we've seen nothing from the Biontech collab but vailed hints about synergistic effect. I can't point to a single thing in the pipeline with the potential to break through
-
but perhaps worse - there is a profound lack of phase 3 programs in the pipeline
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind